Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

1.280 -0.040 (-3.03%)
Streaming Delayed Price Updated: 12:04 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Chemomab Therapeutics Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Chemomab Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver... 
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024
Chemomab Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023
Chemomab Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic this morning as we check out all of the winners and losers worth keeping tabs on for Thursday! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning! 
Via InvestorPlace
Why Children's Place Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of The Children's Place, Inc. (NASDAQ: PLCE) moved lower during Thursday’s session following weak quarterly earnings. 
Via Benzinga
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday! 
Via InvestorPlace
Crude Oil Falls 2%; TJX Issues Weak Earnings Outlook
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 150 points on Wednesday. The Dow traded up 0.46% to 34,989.30 while the NASDAQ rose 0.16% to 14,116.28. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
Via Benzinga
US Stocks Gain; Producer Prices Fall In October
U.S. stocks traded higher this morning, with the Dow Jones gaining around 90 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.27% to 34,922.07 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why is Liver Disease Focused Chemomab Stock Trading Higher Today?
Chemomab Therapeutics Ltd (NASDAQ: CMMB) shares are trading higher after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC),  
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
What's Going On With Chemomab Therapeutics Stock Today
Chemomab Therapeutics Ltd (NASDAQ: CMMB) reported topline results from secondary Phase 2a liver fibrosis trial analyses assessing CM-101 in patients with  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.